95322-54-6

Upstream product

• 14062-24-9 4-chloro-benzeneacetic acid, ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 91632-27-8 4-(4-Chloro-phenyl)-2H-isoxazol-5-one 
• 1236064-81-5 ethyl α-[[(2-chloro-4-pyridinyl)amino]methylene]-(4-chlorophenyl)acetate 
• 91632-34-7 4,4'-Bis-(4-chloro-phenyl)-4'H-[2,4']biisoxazolyl-5,5'-dione 
• 91632-58-5 (Z)-2-(4-Chloro-phenyl)-3-{[1-(4-chloro-phenyl)-1-cyano-meth-(Z)-ylidene]-amino}-acrylic acid methyl ester 
• 91632-53-0 (Z)-2-(4-Chloro-phenyl)-3-{[1-(4-chloro-phenyl)-1-cyano-meth-(Z)-ylidene]-amino}-acrylic acid 
• 91632-47-2 (Z)-3-(4-Chloro-benzoylamino)-2-(4-chloro-phenyl)-acrylic acid 
• 91632-40-5 2,5-bis(4-chlorophenyl)-6H-1,3-oxazin-6-one 

Relevant academic research and scientific papers

Br?nsted acid mediated cyclizations of ortho-aryl(ethynyl)pyrimidines

A high-yielding procedure for the synthesis of 5-aryl-4-(arylethynyl)pyrimidines from easily available 2-aryl-3-hydroxyacrylates is reported. These pyrimidines readily undergo cyclization in strong Br?nsted acids and, depending on the substitution in alky

PROCESS FOR MAKING AMINO ACID COMPOUNDS

The invention provides new processes for making and purifying amino acid compounds, which are useful in the preparation of AKT inhibitors used in the treatment of diseases such as cancer, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.

alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof

The present application is related to compounds represented by Formula I, which are novel allosteric modulators of α7nAChR. The application also discloses the treatment of disorders that are responsive to modulation of acetylcholine action on α7nAChR in a

Unusual anion effects in the iron-catalyzed formation of 3-hydroxyacrylates from aromatic aldehydes and ethyl diazoacetate

Due to the lability of one of the CO ligands in irans-[Fe(PNP)(CO) 2Cl]+ this compound is an efficient catalyst for the coupling of a series of aromatic aldehydes with ethyl diazoacetate (EDA), which give, in most cases, selectively 3-hydroxyacrylates rather than β-oxo esters. This reaction is strongly dependent on the nature of the counterion, Whereas with BF4- the reaction proceeds with conversions up to 90%, in the case of the counterions NO3-, CF 3COO-, CF3SO3-, SbF 6-, and BAr'4- [Ar' = 3,5-(CF 3)2C6H3] no reaction took place. In the case of PF6- only up to 20% conversion was achieved. A conceivable mechanism for the coupling of aromatic aldehydes with EDA was established by means of DFT/B3LYP calculations, which allowed the rationalization of both the chemoselectivity and the role of the counterions.

NEUROLOGICALLY-ACTIVE COMPOUNDS

The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.